EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial

Benjamin Haaland, Samuel P Dickson, Agustin Fernández Santana, Rudolph E Tanzi, Bruno Dubois, Oliver Peters, Timo Grimmer, Joshua Christensen iD, Craig Mallinckrodt, Achim Schneeberger iD, Suzanne B Hendrix

Journal of Alzheimer’s Disease · 2025

DOI: 10.1177/13872877251375985 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Benjamin Haaland und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pentara Corporation, Millcreek, UT, USA. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, Adjuvants, Vaccine, Aluminum Hydroxide, Alzheimer Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Advantage Therapeutics Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The AFF006 trial (NCT01117818) provided unexpected evidence of benefits of the vaccine adjuvant AD04 (aluminum oxyhydroxide) in patients with early Alzheimer's disease (AD), compared with AD02, a vaccine consisting of a peptide that mimics the N-terminal region of human amyloid-β (Aβ) conjugated with keyhole limpet hemocyanin.

Objective

The objective of this post hoc analysis was to assess whether this unexpected benefit of AD04 was an artifact of multiple testing (i.e., type I error inflation) or a robust result.

Methods

In this post hoc assessment, we used permutation testing to estimate type I error inflation due to the evaluation of multiple outcomes in AFF006. Efficacy was assessed using a patient-level global statistical test combining composite endpoints of cognition, function, and global AD. In addition, we examined the observed treatment benefits of AD04 in the context of effects observed in trials of aducanumab, donanemab, and lecanemab, monoclonal anti-Aβ antibodies that received regulatory approval for AD.

Results

The global statistical test suggested a treatment benefit of AD04 versus ineffective AD02 arms, even after accounting for multiplicity (primary methodology p-value, 0.03; permutation test p-value, 0.02). The observed effect estimates for AD04 compared favorably with approved monoclonal antibodies.

Conclusions

Post-hoc analyses are hypothesis generating rather than confirmatory. Adjusting for multiplicity using permutation testing can determine whether post-hoc effects are worth pursuing, or unlikely to be confirmed. These analyses have motivated a follow-up prospective randomized controlled trial, ADVANCE (EudraCT 2022-003532-73), in which optimized AD04 dosing will be compared to placebo in early AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicAdjuvants, VaccineAluminum HydroxideAlzheimer DiseaseAlzheimer VaccinesAgedFemaleHumansMaleMiddle AgedAmyloid beta-PeptidesDouble-Blind MethodProof of Concept StudyTreatment Outcome

Stichwörter der Autor:innen

Alzheimer's diseasealuminumglobal statistical testpermutation testvaccine adjuvant

Substanzen

Adjuvants, ImmunologicAdjuvants, VaccineAluminum HydroxideAlzheimer VaccinesAmyloid beta-Peptides

Autor:innen und Institutionen

  • Pentara Corporation, Millcreek, UT, USA.
  • Advantage Therapeutics, Miami, FL, USA.
  • Genetics and Aging Research Unit, McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Alzheimer Research Center IM2A, GH Pitié-Salpêtrière, Paris, France.
  • Department of Psychiatry and Neurosciences, CBF, Charité, Berlin, Germany.
  • School of Medicine and Health, Klinikum rechts der Isar, Centre for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.

ORCID-Profile: Joshua Christensen, Achim Schneeberger

Förderung

  • Advantage Therapeutics Inc.

Zitieren

APA

Haaland, B., Dickson, S. P., Santana, A. F., Tanzi, R. E., Dubois, B., Peters, O., Grimmer, T., Christensen, J., Mallinckrodt, C., Schneeberger, A., & Hendrix, S. B. (2025). Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251375985

Vancouver

Haaland B, Dickson SP, Santana AF, Tanzi RE, Dubois B, Peters O, et al. Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877251375985

BibTeX
@article{Haaland2025,
  author = {Haaland, Benjamin and Dickson, Samuel P and Santana, Agustin Fernández and Tanzi, Rudolph E and Dubois, Bruno and Peters, Oliver and Grimmer, Timo and Christensen, Joshua and Mallinckrodt, Craig and Schneeberger, Achim and Hendrix, Suzanne B},
  title = {Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial},
  journal = {Journal of Alzheimer’s Disease},
  year = {2025},
  doi = {10.1177/13872877251375985}
}
Kostenlos starten →